Events
QB3 Webinar: Fady Malik, Cytokinetics. “Muscle Biology and Therapies for Heart Failure and Hypertrophic Cardiomyopathy”
Register for the Livestream
Fady Malik is one of only a few scientists who have taken a drug all the way from discovery to patients. Fady attended Berkeley for undergrad and earned his MD and PhD from UCSF, where he ultimately became clinical professor of interventional cardiology. In parallel, he joined Cytokinetics at its inception to pursue the discovery and development of new therapies, and now leads R&D there as executive VP. He was instrumental in the pivot from cancer to muscle biology at Cytokinetics, which is advancing a pipeline of therapies for cardiovascular and neuromuscular diseases of impaired muscle function. One of its most mature programs is aficamten, a small molecule inhibitor of cardiac myosin that is currently under review at FDA as a new therapy for hypertrophic cardiomyopathy. Join us to learn from Fady’s first-hand experience on the long road from lab bench to market.
About the Speaker
Fady Malik, MD, PhD, is Executive VP of Research and Development at Cytokinetics.
Fady has led Research and Development since 2014 and been with Cytokinetics since its inception in 1998 when he joined its founders to participate in the launch of the company. Early on, Fady recognized the potential therapeutic utility of modulating the sarcomere of cardiac and skeletal muscle and led discovery and development efforts giving rise to Cytokinetics’ current portfolio of early- to late-stage development programs targeting muscle contractility for the treatment of cardiovascular and neuromuscular diseases.
Fady is an internationally recognized cardiovascular physician-scientist, an inventor on more than 20 issued patents, and has authored or co-authored over 60 publications appearing in prominent journals such as Science, Nature Medicine, the Lancet, and the New England Journal of Medicine. He currently holds an appointment in the Cardiology Division of the University of California, San Francisco, as a Clinical Professor of Medicine and until 2019 was an Attending Interventional Cardiologist at the San Francisco Veterans Administration and UCSF Medical Centers.
Fady serves on the Board of Directors for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT).
Fady received a B.S. in bioengineering from the University of California at Berkeley, and a M.D./Ph.D. from the University of California at San Francisco where he also completed an internal medicine residency and fellowship in cardiology.
Fady is a native San Franciscan who enjoys travel, outdoor sports such as cycling, running and skiing, and spending time with his wife and three children.
